Evidence map›Paper›PMID 28597184›Full record

ArticleJournal of neuro-oncology2017

Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme.

Yu Qin, Masamichi Takahashi, Kristopher Sheets, Horacio Soto, Jessica Tsui, Panayiotis Pelargos, Joseph P Antonios, Noriyuki Kasahara, Isaac Yang, Robert M Prins and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Genome-Wide SNPs and InDels Characteristics of Three Chinese Cattle Breeds.Animals : an open access journal from MDPI · 2019
    Article
  13. Article
  14. Article
  15. Genetic Deletion ofFrontiers in medicine · 2019
    Article
  16. Article
  17. Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors.Journal of experimental & clinical cancer research : CR · 2018
    Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Yu QinDepartment of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Masamichi TakahashiDepartment of Neurosurgery, National Cancer Center, Tokyo, Japan.
Kristopher SheetsDepartment of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Horacio SotoDepartment of Neurosurgery, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Jessica TsuiDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Panayiotis PelargosDepartment of Neurosurgery, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Joseph P AntoniosDepartment of Neurosurgery, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Noriyuki KasaharaDepartment of Cell Biology and Pathology, University of Miami, Miami, FL, 33136, USA.
Isaac YangDepartment of Neurosurgery, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Robert M PrinsDepartment of Neurosurgery, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Jonathan BraunDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Lynn K GordonDepartment of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Madhuri WadehraDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, 90095, USA. mwadehra@mednet.ucla.edu.
University of California, Los Angeles · USUCLA Jonsson Comprehensive Cancer CenterUniversity of Miami · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
Using EMP2 for Image Guided Drug Delivery for Breast CancerR01CA163971 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI OLAFSEN, TOVE, WADEHRA, MADHURI · 2012 to 2016
$1.6M
NCATS NIH HHS UL1 TR001881NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA163971NIDDK NIH HHS P30 DK041301
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumor and is associated with an extremely poor clinical prognosis. One pathologic hallmark of GBM is excessive vascularization with abnormal blood vessels. Extensive investigation of anti-angiogenic therapy as a treatment for recurrent GBM has been performed. Bevacizumab, a monoclonal anti-vascular endothelial growth factor A (VEGF-A), suggests a progression-free survival benefit but no overall survival benefit. Developing novel anti-angiogenic therapies are urgently needed in controlling GBM growth. In this study, we demonstrate tumor expression of epithelial membrane protein-2 (EMP2) promotes angiogenesis both in vitro and in vivo using cell lines from human GBM. Mechanistically, this pro-angiogenic effect of EMP2 was partially through upregulating tumor VEGF-A levels. A potential therapeutic effect of a systemic administration of anti-EMP2 IgG1 on intracranial xenografts was observed resulting in both significant reduction of tumor load and decreased tumor vasculature. These results suggest the potential for anti-EMP2 IgG1 as a promising novel anti-angiogenic therapy for GBM. Further investigation is needed to fully understand the molecular mechanisms how EMP2 modulates GBM pathogenesis and progression and to further characterize anti-EMP2 therapy in GBM.

Indexed as

AnimalsAntigens, CD34Cell Line, TumorCell MovementFemaleGene Expression Regulation, NeoplasticGlioblastomaGreen Fluorescent ProteinsHumansHuman Umbilical Vein Endothelial CellsImmunoglobulin GMembrane GlycoproteinsMiceMice, NudeMicroarray AnalysisNeovascularization, PathologicAntigens, CD34EMP2 protein, humanGreen Fluorescent ProteinsImmunoglobulin GMembrane GlycoproteinsRNA, Small InterferingVascular Endothelial Growth Factor AAngiogenesisEMP2GBMImmunotherapy

Identifiers

PMID28597184
PMCPMC5695892
OpenAlexW2622881765

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.